SCHEMBL6774596

SCHEMBL6774596

O=C(Nc1ccccc1Cl)Nn1ncc2cncnc21

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.47
RAB9A P51151 3/20 0.45
HTT P42858 2/20 0.45
MAPT P10636 1/20 0.45
POLB P06746 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.44
CASP3 P42574 2/20 0.44
SENP7 Q9BQF6 2/20 0.44
SENP8 Q96LD8 1/20 0.44
NPC1 O15118 2/20 0.44
MCL1 Q07820 1/20 0.43
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 1/20 0.41
CYP2C19 P33261 1/20 0.41
ROCK2 O75116 1/20 0.40
ROCK1 Q13464 1/20 0.40
EPHB3 P54753 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10458447 0.68 KDM4E (0.72) KDM4ERAB9AHTTMAPTPOLB
SCHEMBL6880333 0.67 EGFR (0.38) KDM4EKMT2AMEN1CYP1A2CYP3A4
SCHEMBL6774600 0.66 KDM4E (0.50) KDM4ERAB9AHTTMAPTPOLB
SCHEMBL6774589 0.65 KDM4E (0.49) KDM4ERAB9AHTTMAPTPOLB
SCHEMBL30763135 0.65 MCL1 (0.66) KDM4ERAB9AHTTPOLBSMN1; SMN2
SCHEMBL9901399 0.65 MCL1 (0.66) KDM4ERAB9AHTTPOLBSMN1; SMN2
SCHEMBL5553023 0.64 HTT (0.47) KDM4ERAB9AHTTMAPTSMN1; SMN2
SCHEMBL11449284 0.64 CYP1A2 (0.65) KDM4ERAB9AHTTMAPTPOLB
SCHEMBL11563061 0.62 CYP1A2 (0.58) KDM4ERAB9AHTTMAPTPOLB
SCHEMBL22926342 0.62 HTT (1.00) KDM4ERAB9AHTTMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6806274-B1 IMMUNOREGULATION OR IMMUNOSUPPRESSIVE AGENTS; TYROSINE KINASE INHIBITORS; PREVENTING ORGAN TRANSPLANT REJECTION; AUTOIMMUNE CONDITIONS; REDUCED SIDE EFFECTS ASTRAZENECA UK LIMITED (GB) 2004-10-19 US disclosed